AU2017254774B2 - Chemotherapy improvements - Google Patents

Chemotherapy improvements Download PDF

Info

Publication number
AU2017254774B2
AU2017254774B2 AU2017254774A AU2017254774A AU2017254774B2 AU 2017254774 B2 AU2017254774 B2 AU 2017254774B2 AU 2017254774 A AU2017254774 A AU 2017254774A AU 2017254774 A AU2017254774 A AU 2017254774A AU 2017254774 B2 AU2017254774 B2 AU 2017254774B2
Authority
AU
Australia
Prior art keywords
composition
administered
platin
cancer
taxane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017254774A
Other languages
English (en)
Other versions
AU2017254774A1 (en
Inventor
Graham Kelly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Noxopharm Ltd
Original Assignee
Noxopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxopharm Ltd filed Critical Noxopharm Ltd
Publication of AU2017254774A1 publication Critical patent/AU2017254774A1/en
Application granted granted Critical
Publication of AU2017254774B2 publication Critical patent/AU2017254774B2/en
Priority to AU2021266308A priority Critical patent/AU2021266308B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017254774A 2016-04-22 2017-04-21 Chemotherapy improvements Ceased AU2017254774B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021266308A AU2021266308B2 (en) 2016-04-22 2021-11-11 Chemotherapy improvements

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662326144P 2016-04-22 2016-04-22
US62/326,144 2016-04-22
PCT/AU2017/050363 WO2017181242A1 (en) 2016-04-22 2017-04-21 Chemotherapy improvements

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021266308A Division AU2021266308B2 (en) 2016-04-22 2021-11-11 Chemotherapy improvements

Publications (2)

Publication Number Publication Date
AU2017254774A1 AU2017254774A1 (en) 2018-11-15
AU2017254774B2 true AU2017254774B2 (en) 2021-10-21

Family

ID=60115481

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017254774A Ceased AU2017254774B2 (en) 2016-04-22 2017-04-21 Chemotherapy improvements
AU2021266308A Ceased AU2021266308B2 (en) 2016-04-22 2021-11-11 Chemotherapy improvements

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021266308A Ceased AU2021266308B2 (en) 2016-04-22 2021-11-11 Chemotherapy improvements

Country Status (6)

Country Link
US (1) US20190117620A1 (enExample)
EP (2) EP4035667A1 (enExample)
JP (2) JP6928000B2 (enExample)
AU (2) AU2017254774B2 (enExample)
CA (1) CA3058505A1 (enExample)
WO (1) WO2017181242A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3439642A4 (en) * 2016-04-06 2019-11-13 Noxopharm Limited IMPROVEMENTS IN RADIOTHERAPY
EP3439644B1 (en) * 2016-04-06 2022-01-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
CA3058500A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Targeted drug delivery
AU2017254774B2 (en) * 2016-04-22 2021-10-21 Noxopharm Limited Chemotherapy improvements
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030662A1 (en) * 2002-10-02 2004-04-15 Novogen Research Pty Ltd Combination chemotherapy compositions and methods
WO2005049008A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
WO2006032086A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO203996A0 (en) 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
US8178123B2 (en) * 2001-08-29 2012-05-15 Femina Pharma Incorporated Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
AU2017254774B2 (en) 2016-04-22 2021-10-21 Noxopharm Limited Chemotherapy improvements

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004030662A1 (en) * 2002-10-02 2004-04-15 Novogen Research Pty Ltd Combination chemotherapy compositions and methods
WO2005049008A1 (en) * 2003-11-19 2005-06-02 Novogen Research Pty Ltd Combinational radiotherapy and chemotherapy compositions and methods
WO2006032086A1 (en) * 2004-09-21 2006-03-30 Novogen Research Pty Ltd Chroman derivatives, medicaments and use in therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCPHERSON et al., "Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells", British Journal of Cancer, (2009), vol. 100, no. 4, pages 649 - 655 *

Also Published As

Publication number Publication date
AU2021266308A1 (en) 2021-12-09
AU2017254774A1 (en) 2018-11-15
CA3058505A1 (en) 2017-10-26
JP7193591B2 (ja) 2022-12-20
EP3445347B1 (en) 2022-03-30
EP4035667A1 (en) 2022-08-03
AU2021266308B2 (en) 2022-12-01
WO2017181242A1 (en) 2017-10-26
EP3445347A4 (en) 2019-10-30
JP2019513812A (ja) 2019-05-30
JP6928000B2 (ja) 2021-09-01
US20190117620A1 (en) 2019-04-25
EP3445347A1 (en) 2019-02-27
JP2021169534A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
AU2021266308B2 (en) Chemotherapy improvements
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
RU2662298C2 (ru) Лечение рака комбинацией плинабулина и таксана
RU2508116C2 (ru) Способ и композиции для лечения рака
PT2127652E (pt) Agente libertador da hormona estimuladora dos folículos
JP2012144512A (ja) 脳腫瘍を治療するための医薬組成物又は脳腫瘍細胞のテモゾロミド耐性を低減させるための医薬組成物、及びその使用
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
EP3439644B1 (en) Isoflavonoid composition with improved pharmacokinetics
WO2018170457A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
TW200940062A (en) Combination comprising paclitaxel for treating ovarian cancer
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
JP2016519157A (ja) ガネテスピブを用いる特定癌の治療レジメン
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
WO2018157081A1 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN111773388B (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
WO2025194059A1 (en) Combination treatment regimens - smarca2 degrader with taxane anticancer agent
HK1138797A (zh) 肝癌治疗剂
HK1178458A (en) Therapeutic agent for liver cancer
JP2010111582A (ja) リファンピシンを成分とする肝臓癌治療剤
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1202423B (en) Combination therapy with a topoisomerase inhibitor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired